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Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense
against pathogens, whereas accelerated production of IL-6 plays a signiﬁcant pathological role in
various diseases. Clinical trials have demonstrated the efﬁcacy of tocilizumab, a humanized anti-
IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman’s disease or juvenile idio-
pathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since
IL-6 has been demonstrated to play a signiﬁcant role in the development of various other autoim-
mune and inﬂammatory diseases, tocilizumab can be expected to become a novel drug for such dis-
eases as well.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Interleukin-6
Interleukin-6 (IL-6) is a secreted 21 kDa glycoprotein with a
four-helix bundle structure containing 185 amino acids [1]. The
IL-6 receptor (IL-6R) system consists of two chains, one being the
IL-6 receptor, which is the 80-kDa IL-6-binding subunit with a
short cytoplasmic domain [2], and the other gp130, which is the
130-kDa membrane glycoprotein and transduces the IL-6 signal
into cells via the cytoplasmic domain (Fig. 1) [3]. The broad range
of expression of gp130 on various cells suggests the pleiotropic ef-
fects of IL-6, since naturally occurring soluble IL-6R (sIL-6R) exists
in human serum, and even in cells lacking IL-6R on their surface,
the IL-6/sIL-6R complex can transduce the IL-6 signal on gp130-
expressing cells [4]. After binding of IL-6 to IL-6R, the IL-6/IL-6R
complex combines with gp130 and induces the latter’s homodi-
merization, which triggers activation of Janus kinase family tyro-
sine kinases (JAKs), then recruits and activates signal transducer
and activator of transcription (STAT)3 and the SH2-domain con-
taining protein tyrosine phosphatase-2 (SHP2) [5]. Next, activated
STAT3 translocates into the nucleus and regulates transcription for
various sets of genes. SHP2 associates with adaptor moleculecal Societies. Published by Elsevier
munoregulation, Osaka Uni-
amada-oka, Suita City, Osaka
imoto).growth factor receptor-bound protein 2 (Grb2) and then activates
the son of sevenless (SOS)/Ras–Raf–MEK–MAP kinase pathway
[6]. IL-6R is a cognate binding receptor for IL-6, whereas gp130 is
shared by IL-6 family cytokines including leukemia inhibitory fac-
tor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF),
IL-11, cardiotrophin 1 (CTF1) and cardiotrophin-like cytokine
(CLC) and IL-27 [7]. These cytokines often show overlapping func-
tions with those of IL-6. The functional redundancy of various cyto-
kines is explained by the model of common signal transducer [8].
IL-27 is a heterodimeric cytokine that consists of p28 and EBI3
(Epstein-Barr virus-induced gene 3) subunits. IL-27p28 was re-
cently shown to interact with gp130, but it can not induce
gp130-mediated signaling without EBI3 and inhibits functions of
IL-6 and IL-11 as an antagonist of gp130 [9], whereas IL-27p28
after binding with cytokine-like factor 1 (CLF) even in the absence
of EBI3 was demonstrated to interact with IL-6R and induce signal-
ing on NK and T cells expressing IL-27Ra (WSX-1) and gp130 [10].
IL-6 was ﬁrst recognized as a T-cell-derived factor, which in-
duces B-cell differentiation into antibody producing cells. This
cytokine was variously known as B-cell differentiation factor,
B-cell stimulating factor-2, interferon (IFN)-b2, 26-kDa protein,
hybridoma growth factor and hepatocyte-stimulating factor before
it was recognized that all these entities were identical and the
namewas uniﬁed as IL-6 [11]. Subsequent in vitro studies, analyses
of IL-6 transgenic mice and experimental animal models have
shown that IL-6 acts not only on B cells but also on T cells,B.V. Open access under CC BY-NC-ND license.
Fig. 1. A pleiotropic activity of IL-6. IL-6 induces homodimerization of gp130 and activates JAK family tyrosine kinases, while JAKs induce tyrosine phosphorylation of gp130
and recruitment of STAT3 via the SH2 domain. This is followed by phosphorylation of STAT3 by JAKs and translocation into the nucleus to regulate gene activation.
Recruitment of SHP-2 to gp130 leads via Grb2 to activation of SOS/Ras, followed by activation of the Raf–MEK–MAP kinase pathway. A humanized anti-IL-6R antibody,
tocilizumab, binds to soluble and membranous IL-6R and competitively blocks binding of IL-6 to IL-6R or sIL-6R. IL-6 induces cell differentiation or speciﬁc gene expression,
production of acute-phase proteins in hepatocytes, reduction of iron and zinc concentration, immunoglobulin induction in B cells, cytotoxic T-cell differentiation and Th17
differentiation in T cells. IL-6 also acts on synovial ﬁbroblast cells to produce RANKL and VEGF, which promote differentiation of osteoclasts and angiogenesis. Furthermore,
IL-6 stimulates dermal ﬁbroblasts to produce collagen. Abbreviations: JAK, Janus kinase; STAT, signal transducer and activator of transcription; IL-6R, IL-6 receptor; sIL-6R,
soluble IL-6 receptor; RANKL, receptor activator of NF-kappaB ligand; VEGF, vascular endothelial growth factor.
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addition to performing a variety of functions [12]. In liver, IL-6
strongly induces wide spectrum of acute phase proteins such as
C-reactive protein (CRP), serum amyloid protein A, haptoglobin,
a1-antichymotrypsin and ﬁbrinogen, whereas IL-6 reduces ﬁbro-
nectin, albumin and transferrin (Fig. 1). Hypoferremia and hypo-
zincemia seen in inﬂammatory responses are also induced by IL-
6. Induction of hepcidin by IL-6 in liver causes hypoferremia by
blocking iron transporter ferroportin 1 on gut, resulting in anemia
of inﬂammation [13]. Induction of zinc transporter Zip14 in liver
increases zinc uptake into hepatocytes and leads to hypozincemia
[14]. In lymphocytes, IL-6 affects not only B cells but also T cells.
CD4 positive T helper cells show distinct effector functions after
their differentiation. A subset of IL-17-producing T helper cells
(Th17) reportedly plays a crucial role in the induction of autoim-
mune tissue injury. IL-6, together with TGF-b, has been shown to
be essential for Th17 differentiation from naive CD4 T cells [15].
IL-6 also acts on CD8 positive T cells to induce cytotoxic T cells
[16]. In addition to the effects of IL-6 on acquired immunity, IL-6
has an important function in the early phase of infections. IL-6 is
produced by monocytes and macrophages after the stimulation
of Toll-like receptors (TLRs) with motifs of microbes conserved
via the MyD88 (myeloid differentiation factor 88)-dependent path-
way [17]. The initial inﬁltration of neutrophils is observed in the
focus of acute infection. IL-6 orchestrates the switch in leukocyterecruitment from neutrophils to more sustained monocytic cells
that develop acquired immune responses [18]. IL-6 is also one of
the key cytokines in the pathogenesis of rheumatoid arthritis
(RA). High levels of the IL-6/sIL-6R complex in synovial ﬂuids in-
duce osteoclast-like cell formation, which is responsible for joint
destruction [19]. Moreover, IL-6 production in bone marrow stro-
mal cells induces receptor activator of NF-kappaB ligand (RANKL),
which is an essential factor for the differentiation and activation of
osteoclasts and bone resorption [20], and the increase in osteoclast
development is mediated by IL-6 after postmenopausal estrogen
loss [21]. Enhanced angiogenesis and increased vascular perme-
ability of synovial tissue are pathological features of RA, and these
characteristics are due to the excess production of vascular endo-
thelial growth factor (VEGF), which is induced by IL-6 in synovial
ﬁbroblasts [22]. The promotional activities of IL-6 such as the pro-
liferation of keratinocytes or collagen production in dermal ﬁbro-
blasts may contribute to autoimmune skin diseases such as
psoriasis and systemic sclerosis, respectively [23,24].
Along with the identiﬁcation of the IL-6 signaling pathway and
its multiple biological activities, the pathological signiﬁcance of IL-
6 for various autoimmune, inﬂammatory diseases and tumor
growth has been the subject of numerous reports. This relationship
was ﬁrst demonstrated in the case of cardiac myxoma. When the
author of this review (T.T.) was a resident, he became the physician
in charge of a patient who had presented with fever, arthritis with
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gammaglobulinemia. The patient suddenly developed a complica-
tion with cerebral thrombosis due to embolism from the atrial
myxoma. In spite of intensive care, the patient died due to multiple
embolisms. The cultured ﬂuid from the myxoma tissues, obtained
by autopsy, yielded a large quantity of IL-6 [25], which suggested
that IL-6 might contribute to chronic inﬂammation and autoimmu-
nity. Subsequent studies have shown that dysregulation of IL-6
production is implicated in the pathogenesis of Castleman’s dis-
ease [26], RA [27] and various other autoimmune, inﬂammatory
and malignant diseases [11,28].2. Development of tocilizumab, a humanized anti-IL-6 receptor
antibody
Because of the biological activities of IL-6 and its pathological
role in diseases, IL-6 blockage was anticipated to constitute a novel
treatment strategy for several inﬂammatory and autoimmune
diseases as well as cancers. In response to these expectations, toc-
ilizumab was developed, which is a humanized anti-IL-6R mono-
clonal antibody of the IgG1 class that was generated by grafting
the complementarity determining regions of a mouse anti-human
IL-6R antibody onto human IgG1. Tocilizumab blocks IL-6-medi-
ated signal transduction through inhibition of IL-6 binding to
membrane and soluble IL-6R (Fig. 1). For RA, the recommended
posology in Japan and the EU is 8 mg/kg once every 4 weeks. In
clinical terms, if the serum tocilizumab concentration is main-
tained more than 1 lg/ml, CRP remains negative [29]. The concen-
tration of CRP is therefore a hallmark for determining whether
tocilizumab completely blocks IL-6 activity in vivo.3. Tocilizumab for autoimmune and inﬂammatory diseases
3.1. Rheumatoid arthritis and reactive AA amyloidosis
RA is a chronic, progressive inﬂammatory disease of the joints
and surrounding tissues that is associated with intense pain, irre-
versible joint destruction and systemic complications [30]. The
biological activities of IL-6 and its elevation in serum as well as
synovial ﬂuids in patients with RA indicate that IL-6 is one of the
key cytokines involved in the development of RA. In fact, animal
models of RA with IL-6 deﬁciency generated by gene knockout or
of IL-6 blockade by using anti-IL-6R antibodies showed a reduction
in the incidence and severity of arthritis [31–35].
Seven Phase III clinical trials of tocilizumab carried out in Japan
and worldwide revealed its efﬁcacy both as monotherapy or com-
bined with disease modifying anti-rheumatic drugs (DMARDs) for
adult patients with moderate to severe RA [36–42]. Moreover, the
SAMURAI [36] and LITHE studies [41] proved that radiological
damage of joints was signiﬁcantly inhibited by tocilizumab treat-
ment. As a result, tocilizumab has now been approved for the treat-
ment of RA in more than 90 countries worldwide [43]. A number of
biologics such as anti-TNF blockers, an IL-1 antagonist, a B-cell
depletor, a T-cell activation blocker and tocilizumab are now avail-
able for the treatment of RA. Currently, one of the anti-TNF drugs is
indicated as a ﬁrst-line biologic [44], but between 14% and 38% of
patients show no or little response to anti-TNF treatment, with as
many as 40% of patients discontinuing these drugs within a year
and 50% within 2 years. The ﬁndings of the RADIATE trial showed
that RA patients who had previously discontinued TNF inhibitors,
mainly due to their inefﬁcacy, showed improvement of 20%, 50%
and 70% according to the American College of Rheumatology
improvement criteria (ACR20/50/70) by 50%, 28.8% and 12.4% of
the patients, respectively, when tocilizumab was administered at
8 mg/kg every 4 weeks [38].Reactive AA amyloidosis is a serious complication of RA, in
which amyloid ﬁbril deposition causes progressive deterioration
in various organs [45]. Serum amyloid A (SAA), an acute phase pro-
tein produced in the liver, is an amyloid A ﬁbril precursor protein.
Since the activation of the SAA gene depends primarily on IL-6
[46,47], tocilizumab administration promptly reduces serum con-
centrations of SAA, just as in the case of C-reactive protein [48].
Three case studies of reactive AA amyloidosis, complicated by RA
reported the ameliorative clinical effect of tocilizumab on gastroin-
testinal symptoms due to intestinal amyloidosis [49–51]. Surpris-
ingly, amyloid A ﬁbril deposits were found to have disappeared
in two cases after three injections of tocilizumab. This suggests
that tocilizumab may be suitable as a ﬁrst-line drug for RA patients
who are complicated with, or are at high risk of developing reactive
AA amyloidosis and indicate the possibility that tocilizumab may
become an innovative drug for reactive AA amyloidosis, caused
by RA and other chronic inﬂammatory disorders [43].
3.2. Castleman’s disease
Castleman’s disease is a lymphoproliferative disease with be-
nign hyperplastic lymph nodes characterized by follicular hyper-
plasia and capillary proliferation accompanied by endothelial
hyperplasia. IL-6 was highly expressed in hyperplastic lymph
nodes and in a patient with a solitary hyperplastic lymph node sur-
gical removal of the involved lymph node led to clinical improve-
ment and reduced serum IL-6 concentration [26], suggesting that
the generation of IL-6 by hyperplastic lymph nodes of Castleman’s
disease is the key element responsible for the various clinical
symptoms. Two open-label clinical trials of tocilizumab for Castle-
man’s disease showed its marked effect in clinical symptoms and
laboratory ﬁndings as well as in histologically determined amelio-
ration [52,53], leading to approval of tocilizumab as an orphan
drug for Castleman’s disease in Japan in 2005.
3.3. Systemic juvenile idiopathic arthritis and adult-onset Still’s
disease
Systemic juvenile idiopathic arthritis (JIA) is a subtype of
chronic childhood arthritis that leads to joint destruction and func-
tional disability, accompanied by systemic inﬂammation [54]. This
long-lasting inﬂammation also causes anemia, impairment of
growth and development, and reactive AA amyloidosis. Moreover,
the acute complication known as macrophage activation syndrome
is associated with serious morbidity. IL-6 has been reported to be
markedly elevated in blood and synovial ﬂuid and the IL-6 level
has been shown to correlate with disease activity [55,56]. The
phase II trial, a dose-escalating trial, started with 2–8 mg/kg of toc-
ilizumab at 2-week intervals was performed for 11 children with
severe and active systemic JIA refractory to high-dose and long-
term corticosteroids. Overall improvement in arthritis and sys-
temic features assessed on an ACR Pedi 30%, 50% and 70% improve-
ment scale was seen in 90.9%, 90.9% and 63.6% of the subjects,
respectively [57]. The randomized, double-blind, placebo-con-
trolled, withdrawal phase III trial for 56 patients with systemic
JIA, who had been refractory to conventional treatment regimens,
showed ACR Pedi 30%, 50% and 70% responses in 91%, 86% and
68% of the patients, respectively [58]. Based on this outstanding
efﬁcacy of tocilizumab for JIA, it was approved as a ﬁrst biologic
drug for the treatment of JIA in Japan. In a recent global phase III
trial (TENDER), 112 patients with severe systemic JIA refractory
to conventional treatments including TNF and IL-1 inhibitors were
enrolled. Patients were randomized to receive placebo or toc-
ilizumab (8 or 12 mg/kg, depending on body weight, every
2 weeks). Signiﬁcantly higher responses for ACR Pedi 50, 70 and
90 were also noted in the tocilizumab group at week 12 (85%,
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the placebo group) [59].
Adult-onset Still’s disease (AOSD) is a chronic inﬂammatory dis-
ease characterized by four cardinal symptoms: spiking fever, eva-
nescent maculopapular rash, arthritis and leukocytosis [60].
Pathologically it resembles systemic JIA and is considered to be
an adult-onset type of systemic JIA. Again, several case and pilot
studies reported that tocilizumab treatment improved clinical
symptoms and signs of AOSD patients who had been refractory
to conventional treatments [61–68]. The clinical efﬁcacy suggests
that tocilizumab may become a ﬁrst line biologic for the treatment
of systemic JIA and AOSD.
3.4. Crohn’s disease
Crohn’s disease (CD) is a chronic inﬂammatory bowel disease of
unknown etiology but IL-6 has been demonstrated to play a signif-
icant role in its development [69]. Elevated levels of IL-6 have been
detected in the blood and in the cultures of colonic mucosal spec-
imens from patients with CD [70,71]. Moreover, in a colitis mouse
model generated by transfer of CD45RBhigh CD4+ T cells into con-
genic SCID mice, rat anti-mouse IL-6 receptor prevented the occur-
rence of signs and symptoms of colitis such as loss of body weight,
bloody diarrhea, and rectal prolapse [72]. A pilot randomized trial
of tocilizumab for 36 patients with active CD demonstrated that
80% of patients given 8 mg/kg every 2 weeks showed a clinical re-
sponse as compared with 31% of placebo-treated patients, indicat-
ing that tocilizumab may also constitute a promising drug for CD
[73]. Colitis associated cancer is the most serious complication of
inﬂammatory bowel diseases. It was reported that IL-6 and STAT3
are required for survival of intestinal epithelial cells and develop-
ment of colitis associated cancer [74], raising a possibility that toc-
ilizumab might suppress the colorectal cancer development.
3.5. Polymyalgia rheumatica and remitting seronegative, symmetrical
synovitis with pitting edema
Polymyalgia rheumatica (PMR) is a chronic inﬂammatory disor-
der that affects the elderly. PMR is characterized by aching and
morning stiffness in the shoulders, neck and pelvic girdles [75].
Although the pathogenesis remains unknown, overproduction of
proinﬂammatory cytokines has been demonstrated to contribute
to its development. Low doses (15–20 mg/day) of corticosteroids
are effective, but 65% of patients with PMR experienced at least
one steroid-related adverse event [76] and 30–39% of patients re-
quired steroid treatment for more than 6 years [77]. Steroid-spar-
ing or alternative drugs thus need to be developed. IL-6 has been
identiﬁed as the only cytokine which is at a consistently high level
in patients with the active form of the disease and it is recognized
as the most sensitive indicator of disease activity and course, so
that IL-6 inhibition with tocilizumab may constitute a novel strat-
egy for the treatment of PMR [75,78,79]. In fact, we reported a dra-
matically beneﬁcial effect of tocilizumab on a patient with long-
standing steroid-refractory PMR complicated by diabetes, osteopo-
rosis and hypertension [80]. After ﬁve injections of tocilizumab at
8 mg/kg every 4 weeks, all symptoms such as the pain in the shoul-
ders and pelvic girdle and morning stiffness improved and the pa-
tient was found to be in remission, so that the prednisolone dose
could be reduced.
Remitting seronegative, symmetrical synovitis with pitting ede-
ma (RS3PE), ﬁrst described by McCarty et al., is an inﬂammatory
disease, characterized by acute onset, symmetrical synovitis, bilat-
eral pitting edema of the hands and feet, and seronegativity for
rheumatoid factor [81]. Since PMR and RS3PE especially affect
the elderly and swelling and pitting edema of the hands and feet
are present in 8–12% of PMR patients, it has been suggested thatPMR and RS3PE might constitute aspects of the same disease
[75]. The etiology of RS3PE is unknown, but IL-6, produced by
the synovial tissues, may play a central role in the development
of RS3PE, either directly, or through induction of VEGF production,
which then leads to synovial hepervascularity and increased vascu-
lar permeability [82–84]. Corticosteroids still constitute the pre-
ferred treatment for RS3PE and in most cases of RS3PE the quick
and the dramatic response is one of the characteristics of the dis-
ease. But for a case of RS3PE refractory to steroids we reported that
tocilizumab treatment ameliorated clinical symptoms and inﬂam-
matory laboratory ﬁndings such as CRP and matrix metalloprotein-
ase-3 (MMP-3) and led to a marked reduction in uptake of Ga-
citrate in the bilateral shoulders and hands [85]. Serum VEGF levels
decreased from 127 to 59 pg/ml. These case reports point to the
possibility that IL-6 blockade may become a novel treatment strat-
egy for PMR and RS3PE.
3.6. Gaint cell arteritis and Takayasu arteritis
The clinical relationship between PMR and giant cell arteritis
(GCA), which involves large and medium-sized arteries, especially
branches of the proximal aorta, is well established, since 16–21% of
patients with PMR also had GCA, and PMR was reportedly present
in 40–60% of patients with GCA [75]. The pathogenesis of GCA re-
mains unclear but CD4+ T cell is the key cell involved and the key
cytokines are IFN-c (essential for granuloma formation) and IL-6
(for systemic response) [86,87].
Takayasu arteritis is another inﬂammatory disease that also in-
volves large and medium-sized arteries. Serum IL-6 levels have
been reported to be highly elevated in patients with Takayasu
arteritis and to correlate positively with disease activity [88,89].
Tocilizumab treatment for a 20-year-old woman with refractory
active Takayasu arteritis improved the clinical manifestations
and the abnormal laboratory ﬁndings [90], suggesting that IL-6
inhibition might be a future treatment option for both Takayasu
arteritis and GCA. In fact, it was reported very recently that toc-
ilizumab treatment induced a rapid remission in ﬁve patients with
GCA and two patients with Takayasu arteritis [91]. This study also
found that four PMR patients became disease-free. Several studies,
however, have suggested that patients with a lower inﬂammatory
response without an increase in IL-6 expression were at a higher
risk of developing ischemic manifestations than were other pa-
tients [92], since the angiogenic activity of IL-6 offers protection
against ischemia in GCA [93]. These ﬁndings indicate that further
clinical studies are required to evaluate the efﬁcacy and safety of
tocilizumab for GCA and Takayasu arteritis.
3.7. Spondyloarthritides
The group of diseases collectively labeled spondyloarthritides
consists of reactive arthritis, ankylosing spondylitis (AS), psoriatic
arthritis, and inﬂammatory bowel disease-related arthritis. These
diseases are characterized by rheumatological manifestations such
as axial involvement, peripheral arthritis and enthesopathy, extra-
articular features, negativity for rheumatoid factor and a genetic
background with a higher than normal positivity of HLA-B27
[94,95].
Reactive arthritis is a disease comprising the clinical triad of
arthritis, urethritis and conjunctivitis [96]. The onset of the disease
is often preceded by bacterial infections either in the urogenital or
gastrointestinal tract. Although the pathogenesis is not clearly
understood, bacterial infections trigger systemic immunoreactions,
and overproductions of proinﬂammatory cytokines including IL-6
has been shown to contribute to the disease development [97–
99]. We reported one case of a reactive arthritis patient who was
successfully treated with tocilizumab [100]. A 20-year-old woman
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the arthritis, she had been treated with corticosteroids, followed by
DMARDs or with immunosuppressive drugs for 4 years, but the
disease activity remained high. When tocilizumab treatment
(8 mg/kg, every 4 weeks) was started, serum CRP and SAA levels
normalized after one injection, and two administrations of toc-
ilizumab led to the disappearance of joint swelling and pain and
complete resolution of symptoms and after ﬁve injections the ser-
um MMP-3 concentration decreased from 692 to 118 ng/ml and
Ga-citrate scintigraphy showed a marked reduction in uptake for
the joints.
The clinical beneﬁts of IL-6 blockade with a murine anti-IL-6
monoclonal antibody (B-E8) or tocilizumab on patients with AS
have also been demonstrated [101–105]. While anti-TNF blockers
have been approved for the treatment of AS, it appears that toc-
ilizumab can substantially improve clinical symptoms in patients
with AS refractory to anti-TNFs, just as found in the treatment
for RA.
3.8. Relapsing polychondritis
Relapsing polychondritis is a very rare disease, characterized by
recurrent inﬂammation and cartilage destruction [106]. Autoim-
mune reactions to antigens present in cartilage such as type II col-
lagen and matrilin and excess generation of proinﬂammatory
cytokines and chemokines are thought to evoke the disease symp-
toms [107]. The acute involvement of laryngotracheal cartilage
causes airway destruction and for such severe cases intensive treat-
ments with corticosteroids, immunosuppressive drugs and biologic
modiﬁers including anti-TNF blockers and IL-1 receptor antagonist
are required. Two patients with relapsing polychondritis that had
been refractory to steroids and immunosuppressive drugs, were
treated with tocilizumab at Osaka University Hospital. The treat-
ment ameliorated clinical symptoms related to upper and lower
airways, so that the prednisolone dose could be reduced [108]. In
one patient, airway narrowing of the bronchus was improved by
one year of treatment while in the other patient Ga-citrate uptake
in the involved cartilages had completely vanished 21 months after
the treatment. Because of the very rare incidence of the disease, it is
difﬁcult to perform well-designed clinical studies, so that there is
an urgent need for reports on clinical experience with tocilizumab
for relapsing polychondritis for evaluation of its efﬁcacy and safety.
3.9. Systemic sclerosis
Progressive systemic sclerosis (SSc), a connective tissue disease,
characterized by ﬁbrosis of the skin and internal organs, pro-
nounced alterations in the microvasculature and frequent cellular
and humoral immunity abnormities [109], is another target dis-
ease for tocilizumab. IL-6 expression is reportedly high in both
the skin and serum of SSc patients and its elevation correlates to
the skin score [110,111]. IL-6 induces collagen production by der-
mal ﬁbroblasts [24], modulates a-smooth muscle actin expression
in dermal ﬁbroblasts, and induces myoﬁbroblasts [112], which are
known to induce sclerotic change [113]. Moreover, blockade of IL-6
receptors has been shown to alleviate skin sclerosis in a mouse
model of SSc (Kitaba et al., under submission). Two SSc patients
who were resistant to conventional treatment regimens were
administered tocilizumab at 8 mg/kg every 4 weeks. After the
treatment, both patients showed softening of the skin with reduc-
tions of 50.7% and 55.7% in the total z-score of Vesmeter, a device
for measuring the physical properties of the skin [114], and of
51.9% and 23% in the modiﬁed Rodnan total skin score [115]. His-
tological examination showed thinning of the collagen ﬁber bun-
dles in the dermis. Since there are few therapeutic drugs for SSc
at the present time [116], these improvements observed in twoSSc patients suggest that tocilizumab appears to be a promising
biologic for the treatment of SSc.
3.10. Polymyositis
Inﬂammatory myopathies encompass a group of acquired mus-
cle disorders that includes polymyositis (PM), dermatomyositis,
and inclusion body myositis. These disorders share the clinical fea-
tures of progressive symmetrical muscle weakness and mononu-
clear inﬂammatory cell inﬁltrates in muscle tissue although they
are generally considered to be distinct diseases with different path-
ophysiologicalmechanisms [117]. Among these inﬂammatorymyo-
pathies, PM appears to be another target disease for tocilizumab
because, ﬁrst, IL-6 has been found to be expressed excessively in
the sera and inﬁltratingmononuclear cells in the muscles of PM pa-
tients [118,119]. Moreover, inﬁltrating cytotoxic T cells in the case
of PM are thought to be involved in muscle ﬁber damage and IL-6
reportedly functions as a killer helper factor in the induction of cyto-
toxic T cells [16]. Third, in a model of myosin-induced experimental
myositis it was shown that control mice developed clinically mani-
festmuscle damage, whereas IL-6-deﬁcientmice showed no clinical
or histological signs of muscle damage [120]. In addition, a recent
study using anothermodel of PM, known as C protein-inducedmyo-
sitis, reported that intraperitoneal administrationof anti-IL-6 recep-
tor antibody couldmodify the severity of myositis [121]. Indeed, we
administered tocilizumab to two PM patients who had been refrac-
tory to corticosteroids plus immunosuppressive drugs. In both pa-
tients creatine phosphokinase normalized and MRI images
showed the disappearance of the high-intensity zones in the thigh
muscles (Narazaki et al., under submission), suggesting that toc-
ilizumab may also be effective as a novel drug for refractory PM.
3.11. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a complex autoimmune
disease of unknown etiology that mainly affects young women
[122]. IL-6 has also been demonstrated to play an important role
in the development of SLE since serum IL-6 levels of SLE patients
were found to be elevated [123–125] and several studies reported
increased urinary excretion of IL-6 by patients with active prolifer-
ating lupus nephritis [125,126]. IL-6 levels in cerebrospinal ﬂuid
were useful for the evaluation of central nervous system (CNS) dis-
ease activity [127]. In murine SLE models, IL-6 blockade by means
of anti-IL-6 receptor or anti-IL-6 antibody was shown to prevent
the onset and progression of the disease [128,129]. On the basis
of these ﬁndings, an open-label phase I dosage-escalation study
was done [130]. Sixteen patients with mild-to-moderate disease
activity were assigned to receive tocilizumab (2 mg/kg for 4 pa-
tients, 4 mg/kg for 6 patients and 8 mg/kg for 6 patients) given
intravenously every other week for 12 weeks. Disease activity
showed signiﬁcant improvement in 8 of the 15 evaluable patients,
while arthritis improved in all 7 patients who had arthritis at base-
line and was resolved in 4 of them. Levels of anti-double-stranded
DNA antibodies decreased by a median of 47% in patients in the 4
and 8 mg/kg groups. As for adverse events, tocilizumab injection
resulted in reversible dosage-related decreases in the absolute
neutrophil count and one patient was withdrawn from the study
because of neutropenia. This result indicates that tocilizumab con-
stitutes a promising therapeutic biologic for SLE and that further
clinical trails will be required to establish the optimal dosing reg-
imen, efﬁcacy and safety.
3.12. Behcet’s disease and uveitis
Behcet’s disease (BD) is a systemic inﬂammatory disease of un-
known etiology, characterized by relapsing episodes of oral aph-
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manifestations including neurological, gastrointestinal and vascu-
lar involvement [131]. IL-6 has been demonstrated to also play a
pathological role in the development of BD, since serum levels of
IL-6 are elevated in active BD patients and some studies found that
the production of IL-6 by T cells and peripheral blood mononuclear
cells from BD patients were enhanced in vitro [132–134]. More-
over, cerebrospinal IL-6 levels are high in BD patients who have
complications related to CNS [135]. These ﬁndings indicate that
IL-6 may be a target molecule for the treatment of BD. We treated
one BD patient suffering from posterior uveitis with tocilizumab.
The patient had suffered from BD for 10 years and had been treated
with colchicine, prednisolone, and cyclosporine. For the recurrent
posterior uveitis, treatment with inﬂiximab, a chimeric anti-TNFa
antibody, was started, and the attacks of uveitis became well con-
trolled. However, 16 months later, when a severe relapse of poster-
ior uveitis occurred, tocilizumab in stead of inﬂiximab was
initiated. Continuous treatment of tocilizumab for 1 year reduced
the number of ocular attacks and the BD Current Activity Form
score (Hirano et al., unpublished observation).
Autoimmune and inﬂammatory uveitis are a group of poten-
tially blinding intraocular inﬂammatory diseases that arise without
a known infectious trigger and are often associated with immuno-
logical responses to unique proteins [136]. They often occur in con-
junction with systemic diseases. Examples include anterior uveitis
associated with juvenile idiopathic arthritis, or ankylosing spondy-
litis, and posterior uveitis in BD, Vogt-Koyanagi-Harada disease
and sarcoidosis. Several studies of animal models indicate that
Th1 and Th17 cells can both play a pathologic role in these diseases
[136]. Blockade of IL-6 signaling by using anti-mouse IL-6 receptor
antibody was recently reported to suppress uveoretinitis through
inhibition of inﬂammatory Th17 responses [137], suggesting that
tocilizumab may constitute a therapeutic option for uveitis.
3.13. Multiple sclerosis and neuromyelitis optica
Multiple sclerosis (MS) is a heterogeneous and complex autoim-
mune disease that is characterized by inﬂammation, demyelina-
tion, and axon degeneration in CNS [138]. The disease is thought
to result from a primary defect in the immune system that targets
components of the myelin sheath, resulting in secondary effects on
neurons. Recent analyses revealed that autoreactive Th17 and B
cells may function as ampliﬁers and effectors in MS [139]. Since
IL-6 is a primary cytokine for the induction of naïve T cells into
Th17 cells and of activated B cells into immunoglobulin-secreting
cells, it is likely that IL-6 is crucial for the development of MS. In
fact, IL-6 or IL-6 transcripts were found to be elevated in the CNS
of MS patients or in a murine experimental autoimmune encepha-
litis (EAE) model of MS [140–143]. Moreover, IL-6 blockade by
anti-IL-6 receptor antibody hampered the development of EAE
through the inhibition of antigen-speciﬁc Th17 cells and Th1 cells
[144], which strongly suggests that MS could be another target dis-
ease for tocilizumab. Neuromyelitis optica (NMO) is a chronic
inﬂammatory CNS disorder predominantly affecting the spinal
cord and optic nerves [145]. Since several recent studies have re-
ported a marked increase of IL-6 in cerebrospinal ﬂuid in patients
with NMO [146,147], it seems that IL-6 blockade will be a novel
therapeutic strategy for NMO.
3.14. Off-label use of tocilizumab for other autoimmune and
inﬂammatory diseases
Case reports have indicated that tocilizumab is effective for
other diseases, including acquired hemophilia A, graft-versus-host
disease (GVHD) and TNF receptor associated periodic syndrome
(TRAPS). Acquired hemophilia A is a rare bleeding disorder charac-terized by the presence of autoantibodies, which inhibit coagula-
tion factor VIII (FVIII) [148]. A patient with acquired hemophilia
A was refractory to corticosteroids and complicated with diabetes
mellitus and glaucoma. Tocilizumab treatment increased the activ-
ity VIII in a rapid and sustained manner, so that the prednisolone
dose could be reduced [149]. A patient with GVHD presenting with
abdominal pain and diarrhea had been refractory to all known
treatments but after tocilizumab was administered at 8 mg/kg
every 2 weeks, symptoms ameliorated in conjunction with histo-
logical improvement. The patient continued to be free of diarrhea
and abdominal cramps even 8 months after the cessation of toc-
ilizumab treatment [150]. TRAPS is a rare autosomal, dominantly
inherited autoinﬂammatory disease, characterized by recurrent
episodes of fever, myalgia, arthralgia, migrating erysipelas and
serositis [151]. It is caused by missense mutations of the 55 kDa
TNF receptor superfamily 1A. Etanercept and anakinra looked like
promising biological drugs, but one patient with TRAPS, whose eta-
nercept or anakinra treatment could not be continued due to ad-
verse events, was treated with tocilizumab 8 mg/kg 4 weekly.
Tocilizumab aborted an evolving acute attack and prevented fur-
ther attacks of TRAPS. During the treatment, the patient needed
no corticosteroids and showed signiﬁcant clinical improvement
in pain, stiffness and well being scores [152]. These case reports
also indicate that tocilizumab can be effective for other autoim-
mune and (auto)inﬂammatory diseases.4. Safety of tocilizumab
Data regarding the safety of tocilizumab have been collected
from RA patients and the overall safety proﬁle is consistent across
all global clinical studies and with the Japanese study program
[43]. Serious adverse events (AEs) comprise serious infections, gas-
trointestinal perforations, and hypersensitivity reactions including
anaphylaxis. The most common AEs were upper respiratory tract
infection, nasopharyngitis, headache, high blood pressure and an
increase in liver enzymes. Changes in laboratory ﬁndings, including
increases in total cholesterol and triglycerides in the blood, and de-
creases in neutrophils and platelets were also reported. A systemic
literature review to assess the risk of AEs in RA patients treated
with tocilizumab reported that pooled odds ratios (ORs) revealed
statistical signiﬁcance for an increased risk of AEs for patients trea-
ted with the 8 mg/kg of tocilizumab plus methotrexate compared
with controls (OR = 1.53; 95% CI 1.26–1.86), as well as a heightened
risk of infection (OR = 1.30; 95% CI 1.07–1.58) [153]. However, no
increases in the incidence of malignancy, tuberculosis reactivation
or hepatitis were seen. The incidence of AEs related to tocilizumab
is comparable to that for other biologics. Patients with Castleman’s
disease treated with tocilizumab for 60 weeks were reportedly to
gain weight from 56 to 61 kg [53]. The weight gain is perhaps
due to the general recovery from chronic inﬂammation, but since
IL-6 deﬁcient mice were shown to develop mature-onset obesity
[154], it might also indicate that long-term blockade of IL-6R will
lead to a metabolic-like condition. Further long-term clinical
evaluations will be required.5. Concluding remarks
IL-6 participates in host defense against environmental patho-
gens and is involved in a broad spectrum of biological events, such
as immune responses, hematopoiesis and acute-phase reactions,
whereas dysregulation of IL-6 production has been implicated in
the pathogenesis of various autoimmune and chronic inﬂamma-
tory diseases. Table 1 lists candidate diseases of additional indica-
tions of tocilizumab. It is clear that tocilizumab shows a dramatic
ameliorative effect on reactive AA amyloidosis through its inhibi-
Table 1
IL-6 signaling blockade by the humanized anti-IL-6 receptor antibody, tocilizumab, is
a novel therapeutic strategy for various autoimmune and inﬂammatory diseases.
Diseases for which tocilizumab has been approved as a therapeutic drug:
RA (in more than 90 countries worldwide) [36–42]
Castleman’s disease (in Japan) [52,53]
Systemic and polyarticular JIA (in Japan) [57–59]
Candidate diseases for tocilizumab therapy:
Systemic autoimmune diseases
SLE [130]
Systemic sclerosis [115]
Giant cell arteritis and Takayasu arteritis [90,91]
Polymyositis
Organ speciﬁc autoimmune diseases
Crohn’s disease [73]
Relapsing polychondritis [108]
Multiple sclerosis, neuromyelitis optica
Acquired hemophilia A [149]
Chronic inﬂammatory diseases
Adult-onset Still’s disease [61–68]
Reactive AA amyloidosis [48–51]
Polymyalgia rheumatica [80,91]
RS3PE [85]
Spondyloarthritides [100,102–105]
Behcet’s disease
Uveitis
GVHD [150]
Autoinﬂammatory diseases (TRAPS) [152]
Tocilizumab has been approved as a biological drug for the treatment of RA, Cas-
tleman’s disease and juvenile idiopathic arthritis, and is expected to be applicable to
various other autoimmune and inﬂammatory diseases.
Abbreviations: RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; SLE, sys-
temic lupus erythematosus; RS3PE, remitting seronegative, symmetrical synovitis
with pitting edema; GVHD, graft-versus-host disease; TRAPS, tumor necrosis factor
associated periodic syndrome.
Fig. 2. IL-6 blockade by tocilizumab may modify imbalance in Th17/Treg. IL-6,
together with TGF-b induces Th17 cell differentiation from naïve T cells while IL-6
inhibits regulatory T cell (Treg) differentiation. The imbalance in Th17/Treg
(Th17 Treg) is believed to lead to the development of various autoimmune and
inﬂammatory diseases. Continuous treatment of tocilizumab, a humanized anti-IL-6
receptor antibody, may repair such imbalance. RORc and RORa are master
transcriptional regulators for Th17 while Foxp3 is a master transcriptional regulator
for Treg. Abbreviations: RORc, retinoic acid receptor c; RORa, retinoic acid receptor
a; Foxp3, forkhead box p3.
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through which tocilizumab exerts its therapeutic effects in various
autoimmune and inﬂammatory diseases are not fully understood.
It has been demonstrated that imbalance in Th17/regulatory T
(Treg) (Th17 Treg) causes the development of several autoim-mune and inﬂammatory disease. IL-6, together with TGF-b induces
Th17 differentiation from naïve T cells, whereas IL-6 inhibits TGF-
b-induced Treg differentiation, indicating that IL-6 is a very impor-
tant factor determining Th17/Treg balance (Fig. 2). Therefore, toc-
ilizumab may lead to repair such imbalance in Th17/Treg [15,155].
Indeed, in several animal disease models, anti-IL-6R antibodies
have been demonstrated to suppress antigen-speciﬁc Th17 differ-
entiation but induce antigen-speciﬁc Treg [137,144,156]. These
evidences may explain why IL-6 blockade is an effective therapeu-
tic strategy for various autoimmune and inﬂammatory disorders.
While this review focused on the potential uses of tocilizumab
for autoimmune and inﬂammatory diseases, it is also potentially
useful for the treatment of malignant diseases including multiple
myeloma, renal cancer, prostate cancer and mesothelioma [28].
Future clinical trials to evaluate the efﬁcacy of tocilizumab for
these diseases and its safety and to clarify the mechanism(s)
through which IL-6 blockade exerts its clinical effects will be
essential for the identiﬁcation of additional indications for toc-
ilizumab therapy.Funding
The Program of Fundamental Studies in Health Sciences of the
National Institute of Biomedical Innovation.Conﬂict of interest
Tadamitsu Kishimoto holds a patent for tocilizumab and re-
ceives royalties for Actemra. The other authors declare no conﬂict
of interest.References
[1] Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T.,
Kashiwamura, S., Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa, S.,
Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T. and Kishimoto, T. (1986)
Complementary DNA for a novel interleukin (BSF-2) that induces B
lymphocytes to produce immunoglobulin. Nature 324, 73–76.
[2] Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi,
T., Hirano, T. and Kishimoto, T. (1988) Cloning and expression of the human
interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241, 825–828.
[3] Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T. and Kishimoto, T. (1990)
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63,
1149–1157.
[4] Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y.,
Yancopoulos, G.D., Taga, T. and Kishimoto, T. (1993) Soluble forms of the
interleukin-6 signal-transducing receptor component gp130 in human serum
possessing a potential to inhibit signals through membrane-anchored gp130.
Blood 82, 1120–1126.
[5] Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K.,
Yamanishi, K., Taga, T. and Kishimoto, T. (1993) IL-6-induced
homodimerization of gp130 and associated activation of a tyrosine kinase.
Science 260, 1808–1810.
[6] Kishimoto, T., Taga, T. and Akira, S. (1994) Cytokine signal transduction. Cell
76, 253–262.
[7] Pﬂanz, S., Hibbert, L., Mattson, J., Rosales, R., Vaisberg, E., Bazan, J.F., Phillips,
J.H., McClanahan, T.K., de Waal Malefyt, R. and Kastelein, R.A. (2004) WSX-1
and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J.
Immunol. 172, 2225–2231.
[8] Kishimoto, T., Akira, S. and Taga, T. (1992) Interleukin-6 and its receptor: a
paradigm for cytokines. Science 258, 593–597.
[9] Stumhofer, J.S., Tait, E.D., Quinn, W.J., Hosken, N., Spudy, B., Goenka, R.,
Fielding, C.A., O’Hara, A.C., Chen, A.C., Jones, M.L., Saris, C.J., Rose-John, S., Cua,
D.J., Jones, S.A., Elloso, M.M., Grotzinger, J., Cancro, M.P., Levin, S.D. and
Hunter, C.A. (2010) A role for IL-27p38 as antagonist of gp130-mediated
signaling. Nat. Immunol. 11, 1119–1126.
[10] Crabe, S., Guay-Giroux, A., Tormo, A.J., Duluc, D., Lissilaa, R., Guilhot, F.,
Mavoungou-Bigouagou, U., Lefouili, F., Cognet, I., Ferlin, W., Elson, G., Jeannin,
P. and Gauchat, J.-F. (2009) The IL-27 p28 subunit binds cytokine-like factor 1
to form a cytokine regulating NK and T cell activities requiring IL-6R for
signaling. J. Immunol. 183, 7692–7702.
[11] Kishimoto, T. (2005) Interleukin-6: from basic science to medicine – 40 years
in immunology. Annu. Rev. Immunol. 23, 1–21.
[12] Kishimoto, T. (1989) The biology of interleukin-6. Blood 74, 1–10.
3706 T. Tanaka et al. / FEBS Letters 585 (2011) 3699–3709[13] Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K. and
Ganz, T. (2004) IL-6 mediates hypoferremia of inﬂammation by inducing the
synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271–
1276.
[14] Liuzzi, J.P., Lichten, L.A., Rivera, S., Blanchard, R.K., Aydemir, T.B., Knutson,
M.D., Ganz, T. and Cousins, R.J. (2005) Interleukin-6 regulates the zinc
transporter Zip14 in liver and contributes to the hypozincemia of the acute-
phase response. Proc. Natl. Acad. Sci. USA 102, 6843–6848.
[15] Kimura, A. and Kishimoto, T. (2010) IL-6: regulator of Treg/Th17 balance. Eur.
J. Immunol. 40, 1830–1835.
[16] Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T. and Kishimoto,
T. (1998) IL-6/BSF-2 functions as a killer helper factor in the in vitro induction
of cytotoxic T cells. J. Immunol. 141, 1543–1549.
[17] Akira, S. and Takeda, K. (2004) Toll-like receptor signalling. Nat. Rev.
Immunol. 4, 499–511.
[18] Hurst, S.M., Wilkinson, T.S., McLoughlin, R.M., Jones, S., Horiuchi, S.,
Yamamoto, N., Rose-John, S., Fuller, G.M., Topley, N. and Jones, S.A. (2001)
IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of
leukocyte recruitment seen during acute inﬂammation. Immunity 14, 705–
714.
[19] Kotake, S., Sato, K., Kim, K.J., Takahashi, N., Udagawa, N., Nakamura, I.,
Yamaguchi, A., Kishimoto, T., Suda, T. and Kashiwazaki, S. (1996) Interleukin-
6 and soluble interleukin-6 receptors in the synovial ﬂuids from rheumatoid
arthritis patients are responsible for osteoclast-like cell formation. J. Bone
Miner. Res. 11, 88–95.
[20] Palmqvist, P., Persson, E., Conaway, H.H. and Lerner, U.H. (2002) IL-6,
leukemia inhibitory factor, and oncostatin M stimulate bone resorption and
regulate the expression of receptor activator of NF-kappa B ligand,
osteoprotegerin, and receptor activation of NF-kappa B in mouse calvariae.
J. Immunol. 169, 3353–3362.
[21] Jilka, R.L., Hangoc, G., Girasole, G., Passeri, G., Williams, D.C., Abrams, J.S.,
Boyce, B., Broxmeyer, H. and Manolagas, S.C. (1992) Increased osteoclast
development after estrogen loss: mediation by interleukin-6. Science 257,
88–91.
[22] Nakahara, H., Song, J., Sugimoto, M., Hagihara, K., Kishimoto, T., Yoshizaki, K.
and Nishimoto, N. (2003) Anti-interleukin-6 receptor antibody therapy
reduces vascular endothelial growth factor production in rheumatoid
arthritis. Arthritis Rheum. 48, 1521–1529.
[23] Grossman, R.M., Krueger, J., Yourish, D., Granelli-Piperno, A., Murphy, D.P.,
May, L.T., Kupper, T.S., Sehgal, P.B. and Gottlieb, A.B. (1989) Interleukin-6 is
expressed in high levels in psoriatic skin and stimulates proliferation of
cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86, 6367–6371.
[24] Duncan, M.R. and Berman, B. (1991) Stimulation of collagen and
glycosaminoglycan production in cultured human adult dermal ﬁbroblasts
by recombinant human interleukin 6. J. Invest. Dermatol. 97, 686–692.
[25] Hirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F.,
Shimizu, M., Murashima, A., Tsunasawa, S., Sakiyama, F. and Kishimoto, T.
(1987) Human B-cell differentiation factor deﬁned by an anti-peptide
antibody and its possible role in autoantibody production. Proc. Natl. Acad.
Sci. USA 84, 228–231.
[26] Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K.,
Nakahata, T., Kawai, H., Tagoh, H., Komori, T., Kishimoto, S., Hirano, T. and
Kishimoto, T. (1989) Pathogenic signiﬁcance of interleukin-6 (IL-6/BSF-2) in
Castleman’s disease. Blood 74, 1360–1367.
[27] Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K.,
Shimizu, M., Maid, R., Feldmann, M. and Kishimoto, T. (1988) Excessive
production of interleukin 6/B cell stimulatory factor-2 in rheumatoid
arthritis. Eur. J. Immunol. 18, 1797–1801.
[28] Nishimoto, N. and Kishimoto, T. (2006) Interleukin-6: from bench to bedside.
Nat. Clin. Pract. Rheumatol. 2, 619–626.
[29] Nishimoto, N., Terao, K., Nakahara, H., Takagi, N. and Kakehi, T. (2008)
Mechanisms and pathologic signiﬁcances in increase in serum interleukin-6
(IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor
antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman
disease. Blood 112, 3959–3964.
[30] Smolen, J.S., Aletaha, D., Koeller, M., Weisman, M.H. and Emery, P. (2007)
New therapies for treatment of rheumatoid arthritis. Lancet 370, 1861–1874.
[31] Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M.,
Katada, Y., Tanaka, T., Suemura, M. and Kishimoto, T. (1998) Interleukin 6
plays a key role in the development of antigen-induced arthritis. Proc. Natl.
Acad. Sci. USA 95, 8222–8226.
[32] Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti,
F., Poli, V. and Ciliberto, G. (1998) Interleukin 6 is required for the
development of collagen-induced arthritis. J. Exp. Med. 187, 461–468.
[33] Sasai, M., Saeki, Y., Ohshima, S., Nishioka, K., Mima, T., Tanaka, T., Katada, Y.,
Yoshizaki, K., Suemura, M. and Kishimoto, T. (1999) Delayed onset and
reduced severity of collagen-induced arthritis in interleukin-6-deﬁcient
mice. Arthritis Rheum. 42, 1635–1643.
[34] Takagi, N., Mihara, M., Moriya, Y., Nishimoto, N., Yoshizaki, K., Kishimoto, T.,
Takeda, Y. and Ohsugi, Y. (1998) Blockade of interleukin-6 receptor
ameliorates joint disease in murine collagen-induced arthritis. Arthritis
Rheum. 41, 2117–2121.
[35] Mihara, M., Kotoh, M., Nishimoto, N., Oda, Y., Kumagai, E., Takagi, N.,
Tsunemi, K., Ohsugi, Y., Kishimoto, T., Yoshizaki, K. and Takeda, Y. (2001)
Humanized antibody to human interleukin-6 receptor inhibits thedevelopment of collagen arthritis in cynomolgus monkeys. Clin. Immunol.
98, 319–326.
[36] Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi,
T., Murata, N., van der Heijde, D. and Kishimoto, T. (2007) Study of active
controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor
(SAMURAI): evidence of clinical and radiographic beneﬁt from an X-ray
reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis.
66, 1162–1167.
[37] Genovese, M.C., McKay, J.D., Nasonov, E.L., Mysler, E.F., da Silva, N.A., Alecock,
E., Woodworth, T. and Gomez-Reino, J.J. (2008) Interleukin-6 receptor
inhibition with TCZ reduces disease activity in rheumatoid arthritis with
inadequate response to disease-modifying antirheumatic drugs: the TCZ in
combination with traditional disease-modifying antirheumatic drug therapy
study. Arthritis Rheum. 58, 2968–2980.
[38] Emery, P., Keystone, E., Tony, H.P., Cantagrel, A., van Vollenhoven, R., Sanchez,
A., Alecock, E., Lee, J. and Kremer, J. (2008) IL-6 receptor inhibition with TCZ
improves treatment outcomes in patients with rheumatoid arthritis
refractory to anti-TNF biologics: results from a 24-week multicentre
randomized placebo controlled trial. Ann. Rheum. Dis. 67, 1516–1523.
[39] Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J.,
Alecock, E., Woodworth, T., Alten, R. and OPTION Investigators (2008) Effect
of interleukin-6 receptor inhibition with tocilizumab in patients with
rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled,
randomized trial. Lancet 371, 987–997.
[40] Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J.
and Kishimoto, T. (2009) Study of active controlled tocilizumab monotherapy
for rheumatoid arthritis patients with an inadequate response to
methotrexate (SATORI): signiﬁcant reduction in disease activity and serum
vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod.
Rheumatol. 19, 12–19.
[41] Kremer, J.L., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.M., Vernon,
E., Ambs, P. and Fleischmann, R. (2010) Tocilizumab inhibits structural joint
damage in rheumatoid arthritis patients with inadequate response to
methotrexate at 1 year: the LITHE study. Arthritis Rheum. (Epub ahead of
print).
[42] Jones, G., Sebba, A., Gu, J., Lowenstein, M.B., Calvo, A., Gomez-Reino, J.J., Siri,
D.A., Tomsic, M., Alecock, E., Woodworth, T. and Genovese, M.C. (2010)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy
in patients with moderate to severe rheumatoid arthritis: the AMBITION
study. Ann. Rheum. Dis. 69, 88–96.
[43] Tanaka, T., Ogata, A. and Narazaki, M. (2010) Tocilizumab for the treatment of
rheumatoid arthritis. Expert Rev. Clin. Immunol. 6, 843–854.
[44] Nam, J.L., Winthrop, K.L., van Vollenhoven, R.F., Pavelka, K., Valesini, G.,
Hensor, E.M., Worthy, G., Landewe, R., Smolen, J.S., Emery, P. and Buch, M.H.
(2010) Current evidence for the management of rheumatoid arthritis with
biological disease-modifying antirheumatic drugs: a systematic literature
review informing the EULAR recommendations for the management of RA.
Ann. Rheum. Dis. 69, 976–986.
[45] Obici, L., Perfetti, V., Palladini, G., Moratti, R. and Merlini, G. (2005) Clinical
aspects of systemic amyloid diseases. Biochim. Biophys. Acta 1753, 11–22.
[46] Hagihara, K., Nishikawa, T., Isobe, T., Song, J., Sugamata, Y. and Yoshizaki, K.
(2004) IL-6 plays a critical role in the synergistic induction of human serum
amyloid A (SAA) gene when stimulated with proinﬂammatory cytokines as
analyzed with an SAA isoform real-time quantitative RT-PCR assay system.
Biochem. Biophys. Res. Commun. 314, 363–369.
[47] Hagihara, K., Nishikawa, T., Sugamata, Y., Song, Y., Isobe, T., Taga, T. and
Yoshizaki, K. (2005) Essential role of STAT3 in cytokine-driven NF-kB-
mediated serum amyloid A gene expression. Genes Cells 10, 1051–1063.
[48] Okuda, Y. and Takasugi, K. (2006) Successful use of a humanized anti-
interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis
complicating juvenile idiopathic arthritis. Arthritis Rheum. 54, 2997–3000.
[49] Nishida, S., Hagihara, K., Shima, Y., Kawai, M., Kuwahara, Y., Arimitsu, J.,
Hirano, T., Narazaki, M., Ogata, A., Yoshizaki, K., Kawase, I., Kishimoto, T. and
Tanaka, T. (2009) Rapid improvement of AA amyloidosis with humanised
anti-interleukin 6 receptor antibody treatment. Ann. Rheum. Dis. 68, 1235–
1236.
[50] Sato, H., Sakai, T., Sugaya, T., Otaki, Y., Aoki, K., Ishii, K., Horizono, H., Otani, H.,
Abe, A., Yamada, N., Ishikawa, H., Nakazono, K., Murasawa, A. and Gejyo, F.
(2009) Tocilizumab dramatically ameliorated life-threatening diarrhea due
to secondary amyloidosis associated with rheumatoid arthritis. Clin.
Rheumatol. 28, 1113–1116.
[51] Inoue, D., Arima, H., Kawanami, C., Takiuchi, Y., Nagano, S., Shimoji, S., Mori,
M., Tabata, S., Yanagita, S., Matsushita, A., Nagai, K., Imai, Y. and Takahashi, T.
(2010) Excellent therapeutic effect of tocilizumab on intestinal amyloid a
deposition secondary to active rheumatoid arthritis. Clin. Rheumatol. 29,
1195–1197.
[52] Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T.,
Kishimoto, T. and Yoshizaki, K. (2000) Improvement in Castleman’s disease
by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56–
61.
[53] Nishimoto, N., Kanukura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S.,
Ikeda, Y., Sasaki, T., Nishioka, K., Hara, M., Taguchi, H., Kimura, Y., Kato, Y.,
Asaoku, H., Kumagai, S., Kodama, F., Nakahara, H., Hagihara, K., Yoshizaki, K.
and Kishimoto, T. (2005) Humanized anti-interleukin-6 receptor antibody
treatment of multicentric Castleman disease. Blood 106, 2627–2632.
T. Tanaka et al. / FEBS Letters 585 (2011) 3699–3709 3707[54] Yokota, S. and Kishimoto, T. (2010) Tocilizumab: molecular intervention
therapy in children with systemic juvenile idiopathic arthritis. Expert Rev.
Clin. Immunol. 6, 735–743.
[55] De Benedetti, F., Pignatti, P., Gerioni, V., Massa, M., Sartirana, P., Caporali, R.,
Montecucco, C.M., Corti, A., Fantini, F. and Martini, A. (1997) Differences in
synovial ﬂuid cytokine levels between juvenile and adult rheumatoid
arthritis. J. Rheumatol. 24, 1403–1409.
[56] Romanovsky, A.A., Almeida, M.C., Aronoff, D.M., Ivanov, A.I., Konsman, J.P.,
Steiner, A.A. and Turek, V.F. (2005) Fever and hypothermia in systemic
inﬂammation: recent discoveries and revisions. Front. Biosci. 10, 2193–2216.
[57] Yokota, S., Miyamae, T., Imagawa, T., Iwata, N., Katakura, S., Mori, M., Woo, P.,
Nishimoto, N., Yoshizaki, K. and Kishimoto, T. (2005) Therapeutic efﬁcacy of
humanized recombinant anti-interleukin-6 receptor antibody in children
with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818–
825.
[58] Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N.,
Umebayashi, H., Murata, T., Miyoshi, M., Tomita, M., Nishimoto, N. and
Kishimoto, T. (2008) Efﬁcacy and safety of tocilizumab in patients with
systemic-onset juvenile idiopathic arthritis: a randomized, double-blind,
placebo-controlled, withdrawal phase III trial. Lancet 371, 998–1006.
[59] De Benedetti, F., Brunner, H., Ruperto, N., Wright, S., Kenwright, A., Cuttica, R.,
Woo, P., Schneider, R., Lovell, D. and Martini, A. (2010) From biology to
classiﬁcation and targeted therapy in juvenile idiopathic arthritis. Ann.
Rheum. Dis. 69 (Suppl. 3), 146.
[60] Fautrel, B. (2008) Adult-onset Still disease. Best Pract. Res. Clin. Rheumatol.
22, 773–792.
[61] Iwamoto, M., Nara, H., Hirata, D., Minota, S., Nishimoto, N. and Yoshizaki, K.
(2002) Humanized monoclonal anti-interleukin-6 receptor antibody for
treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 46,
3388–3389.
[62] Nakahara, H., Mima, T., Yoshino-Hoshino, N., Matsushita, M., Hashimoto, J.
and Nishimoto, N. (2009) A case report of a patient with refractory adult-
onset Still’s disease who was successfully treated with tocilizumab over
6 years. Mod. Rheumatol. 19, 69–72.
[63] De Bandt, M. and Saint-Marcoux, B. (2009) Tocilizumab for multirefractory
adult-onset Still’s disease. Ann. Rheum. Dis. 68, 153–154.
[64] Matsumoto, K., Nagashima, T., Takatori, S., Kawahara, Y., Yagi, M., Iwamoto,
M., Okazaki, H. and Minota, S. (2009) Glucocorticoid and cyclosporine
refractory adult onset Still’s disease successfully treated with tocilizumab.
Clin. Rheumatol. 28, 485–487.
[65] Cunha, M.L., Wagner, J., Osawa, A. and Scheinberg, M. (2010) The effect of
tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-
onset Still’s disease. Rheumatology 49, 1014–1016.
[66] Sumida, K., Ubara, Y., Hoshino, J., Suwabe, T., Hiramatsu, R., Hasegawa, E.,
Hayami, N., Yamanouchi, M., Sawa, N., Takemoto, F. and Takaichi, K. (2010)
Etanercept-refractory adult-onset Still’s disease with thrombotic
thrombocytopenic purpura successfully treated with tocilizumab. Clin.
Rheumatol. 29, 1191–1194.
[67] Yoshimura, M., Makiyama, J., Koga, T., Miyashita, T., Izumi, Y., Torigoshi, T.,
Motokawa, S., Eguchi, K. and Migita, K. (2010) Successful treatment with
tocilizumab in a patient with refractory adult-onset Still’s disease (AOSD).
Clin. Exp. Rheumatol. 28, 141–142.
[68] Perdan-Pirkmajer, K., Praprotnik, S. and Tomsic, M. (2010) A case of
refractory adult-onset Still’s disease successfully controlled with
tocilizumab and a review of the literature. Clin. Rheumatol. 29, 1465–1467.
[69] Itoh, H. (2004) Novel therapy for Crohn’s disease targeting IL-6 signaling.
Expert Opin. Ther. Targets 8, 287–294.
[70] Mitsuyama, K., Toyonaga, A. and Sasaki, E. (1995) Soluble interleukin-6
receptors in inﬂammatory bowel disease: relation to circulating interleukin-
6. Gut 36, 45–49.
[71] Hosokawa, T., Kusugami, K., Ina, K., Ando, T., Shinoda, M., Imada, A., Ohsuga,
M., Sakai, T., Matsuura, T., Ito, K. and Kaneshiro, K. (1999) Interleukin-6 and
soluble interleukin-6 receptor in the colonic mucosa of inﬂammatory bowel
disease. J. Gastroenterol. Hepatol. 14, 987–996.
[72] Yamamoto, M., Yoshizaki, K., Kishimoto, T. and Ito, H. (2000) IL-6 is required
for the development of Th1-cell mediated murine colitis. J. Immunol. 164,
4878–4882.
[73] Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto,
T., Yamamura, T., Azuma, J., Nishimoto, N., Yoshizaki, K., Shimoyama, T. and
Kishimoto, T. (2004) A pilot randomized trial of a human anti-interleukin-6
receptor monoclonal antibody in active Crohn’s disease. Gastroenterology
126, 989–996.
[74] Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S.,
Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L. and Karin, M. (2009) IL-6
and STAT3 are required for survival of intestinal epithelial cells and
development of colitis associated cancer. Cancer Cell 15, 103–113.
[75] Salvarani, C., Cantini, F. and Hunder, G.G. (2008) Polymyalgia rheumatica and
giant-cell arteritis. Lancet 372, 234–245.
[76] Gabriel, S.E., Sunku, J., Salvarani, C., O’Fallon, W.M. and Hunder, G.G. (1997)
Adverse outcomes of anti-inﬂammatory therapy among patients with
polymyalgia rheumatica. Arthritis Rheum. 40, 1873–1878.
[77] Cimmino, M.A., Salvarani, C., Macchioni, P., Gerli, R., Bartoloni, B.E.,
Montecucco, C. and Caporali, R. (2008) Long-term follow-up of polymyalgia
rheumatica patients treated with methotrexate and steroids. Clin. Exp.
Rheumatol. 26, 395–400.[78] Salvarani, C., Cantini, F., Niccoli, L., Macchioni, P., Consonni, D., Bajocchi, G.,
Vinceti, M., Catanoso, M.G., Pulsarelli, L., Meliconi, R. and Boiardi, L. (2005)
Acute-phase reactants and the risk of relapse/recurrence in polymyalgia
rheumatica: a prospective followup study. Arthritis Rheum. 53, 33–38.
[79] Alvarez-Rodriguez, L., Lopez-Hoyos, M., Marin, M.J., Calvo-Alen, J., Blanco, R.,
Aurrecoechea, E., Ruiz-Soto, M. and Martinez-Teboada, V.M. (2010)
Circulating cytokines in active polymyalgia rheumatica. Ann. Rheum. Dis.
69, 263–269.
[80] Hagihara, K., Kawase, I., Tanaka, T. and Kishimoto, T. (2010) Tocilizumab
ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol. 37,
1075–1076.
[81] McCarty, D.J., O’Duffy, J.D., Pearson, J.D. and Hunter, J.B. (1985) Remitting,
seronegative symmetrical synovitis with pitting edema. JAMA 254, 2763–
2767.
[82] Oide, T., Ohara, S., Oguchi, K., Maruyama, M., Yazawa, M., Inoue, K., Sekijima,
Y., Tokuda, T. and Ikeda, S. (2004) Remitting seronegative symmetrical
synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical,
radiological, and cytokine studies of 13 patients. Clin. Exp. Rheumatol. 22,
91–98.
[83] Arima, K., Origuchi, T., Tamai, M., Iwanaga, N., Izumi, Y., Huang, M., Tanaka, F.,
Kamachi, M., Aratake, K., Nakamura, H., Ida, H., Uetani, M., Kawakami, A. and
Eguchi, K. (2005) RS3PE syndrome presenting as vascular endothelial growth
factor associated disorder. Ann. Rheum. Dis. 64, 1653–1655.
[84] Kawashiro, S., Nakano, M., Kawakami, A. and Eguchi, K. (2010) Monitoring of
therapeutic efﬁcacy in a patient with RS3PE syndromes by serologic and
radiographic methods. Rheumatol. Int. 30, 1677–1680.
[85] Tanaka, T., Hagihara, K., Shima, Y., Narazaki, M., Ogata, A., Kawase, I. and
Kishimoto, T. (2010) Treatment of a patient with remitting seronegative,
symmetrical synovitis with pitting oedema with a humanized anti-
interleukin-6 receptor antibody, tocilizumab. Rheumatology 49, 826–828.
[86] Marinez-Taboada, V.M., Alvarez, L., RuizSoto, M., Marin-Vidalled, M.J. and
Lopez-Hoyos, M. (2008) Giant cell arteritis and polymyalgia rheumatica: role
of cytokines in the pathogenesis and implications for treatment. Cytokine 44,
207–220.
[87] Ghosh, P., Borg, F.A. and Dasgupta, B. (2010) Current understanding and
management of giant cell arteritis and polymyalgia rheumatica. Expert Rev.
Clin. Immunol. 6, 913–928.
[88] Park, M.C., Lee, S.W., Park, Y.B. and Lee, S.K. (2006) Serum cytokine proﬁles
and their correlations with disease activity in Takayasu’s arteritis.
Rheumatology 45, 545–548.
[89] Moris, M., Daina, E., Gamba, S., Bonazzola, S. and Remuzzi, G. (1999)
Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic
decisions? Circulation 100, 1788–1790.
[90] Nishimoto, N., Nakahara, H., Yoshio-Hoshino, N. and Mima, T. (2008)
Successful treatment of a patient with Takayasu arteritis using a
humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 58,
1197–1200.
[91] Seitz, M., Reichenbach, S., Bonel, H.M., Adler, S., Wermelinger, F. and Villiger,
P.M. (2011) Rapid induction of remission in large vessel vasculitis by IL-6
blockade. Swiss Med. Wkly (Epub ahead of print).
[92] Cid, M.C., Haernandez-Rodriguez, J., Esteban, M.J., Cebrian, M., Gho, Y.S., Font,
C., Urbano-Marquez, A., Grau, J.M. and Kleinman, H.K. (2002) Tissue and
serum angiogenic activity is associated with low prevalence of ischemic
complications in patients with giant-cell arteritis. Circulation 106, 1664–
1671.
[93] Hernandez-Rodriguez, J., Segarra, M., Vilardell, C., Sanchez, M., Garcia-
Martinez, A., Esteban, M.J., Grau, J.M., Urbano-Marquez, A., Colomer, D.,
Kleinman, H.K. and Cid, M.C. (2003) Elevated production of interleukin-6 is
associated with a lower incidence of disease-related ischemic events in
patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a
potential protective mechanism. Circulation 107, 2428–2434.
[94] Reveille, J.D. and Arnett, F.C. (2005) Spondyloarthritis: update on
pathogenesis and management. Am. J. Med. 118, 592–603.
[95] Braun, J. and Sieper, J. (2007) Ankylosing spondylitis. Lancet 369, 1379–1390.
[96] Wu, I.B. and Schwartz, R.A. (2008) Reiter’s syndrome: the classic triad and
more. J. Am. Acad. Dermatol. 59, 113–121.
[97] Metsarinne, K.P., Nordstrom, D.C., Konttinen, Y.T., Teppo, A.M. and Fyhrquist,
F.Y. (1992) Plasma interleukin-6 and renin substrate in reactive arthritis,
rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol. Int. 12,
93–96.
[98] Straub, R.H., Paimela, L., Peltomaa, R., Scholmerich, J. and Leirisalo-Repo, M.
(2002) Inadequately low levels of steroid hormones in relation to interleukin-
6 and tumor necrosis factor in untreated patients with early rheumatoid
arthritis and reactive arthritis. Arthritis Rheum. 46, 654–662.
[99] Singh, R., Aggarwal, A. and Misra, R. (2007) Th1/Th17 cytokine proﬁles in
patients with reactive arthritis/undifferentiated spondyloarthropathy. J.
Rheumatol. 34, 2285–2290.
[100] Tanaka, T., Kuwahara, Y., Shima, Y., Hirano, T., Kawai, M., Ogawa, M.,
Arimitsu, J., Hagihara, K., Narazaki, M., Ogata, A., Kawase, I. and Kishimoto, T.
(2009) Successful treatment of reactive arthritis with a humanized anti-
interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 61, 1762–
1764.
[101] Wendling, D., Racadot, E., Toussirot, E. and Wijdens, J. (1996) Combination
therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe
spondyloarthropathy. Br. J. Rheumatol. 35, 1330.
3708 T. Tanaka et al. / FEBS Letters 585 (2011) 3699–3709[102] Henes, J.C., Horger, M., Guenaydin, I., Kanz, L. and Koetter, I. (2010) Mixed
response to tocilizumab for ankylosing spondylitis. Ann. Rheum. Dis. 69,
2217–2218.
[103] Wendling, D., Bossert, M. and Prati, C. (2010) Short-term effect of IL-6
inhibition in spondyloarthritis. Joint Bone Spine 77, 624–625.
[104] Brulhart, L., Nissen, M.J., Chevallier, P. and Gabay, C. (2010) Tocilizumab in a
patient with ankylosing spondylitis and Crohn’s disease refractory to TNF
antagonists. Joint Bone Spine 77, 625–626.
[105] Shima, Y., Tomita, T., Ishii, T., Morishima, A., Maeda, Y., Ogata, A., Kishimoto,
T. and Tanaka, T. (2011) Tocilizumab, a humanized anti-interleukin-6
receptor antibody, ameliorated clinical symptoms and MRI ﬁndings of a
patient with ankylosing spondylitis. Mod. Rheumatol. (Epub ahead of print).
[106] Rapini, R.P. and Warner, N.B. (2006) Relapsing polychondritis. Clin. Dermatol.
24, 482–485.
[107] Stabler, T., Piette, J.C., Chevalier, X., Marini-Portugal, A. and Kraus, V.B. (2004)
Serum cytokine proﬁles in relapsing polychondritis suggest monocyte/
macrophage activation. Arthritis Rheum. 50, 3663–3667.
[108] Kawai, M., Hagihara, K., Hirano, T., Shima, Y., Kuwahara, Y., Arimitsu, J.,
Narazaki, M., Ogata, A., Kawase, I., Kishimoto, T. and Tanaka, T. (2009)
Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in
two patients with refractory relapsing polychondritis. Rheumatology 48,
319–320.
[109] Gabrielli, A., Avvedimento, E.V. and Krieg, T. (2009) Scleroderma. N. Engl. J.
Med. 360, 1989–2003.
[110] Hasegawa, M., Sato, S., Fujimoto, M., Ihn, H., Kikuchi, K. and Takehara, K.
(1998) Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6
receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol.
25, 308–313.
[111] Sato, S., Hasegawa, M. and Takehara, K. (2001) Serum levels of interleukin-6
and interleukin-10 correlate with total skin thickness score in patients with
systemic sclerosis. J. Dermatol. Sci. 27, 140–146.
[112] Gallucci, R.M., Lee, E.G. and Tomasek, J.J. (2006) IL-6 modulates alpha-smooth
muscle actin expression in dermal ﬁbroblasts from IL-6-deﬁcient mice. J.
Invest. Dermatol. 126, 561–568.
[113] Kirk, T.Z., Mark, M.E., Chua, C.C., Chua, B.H. and Mayes, M.D. (1995)
Myoﬁbroblasts from scleroderma skin synthesize elevated levels of
collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms
of TIMP-1. J. Biol. Chem. 270, 3423–3428.
[114] Kuwahara, Y., Shima, Y., Shirayama, D., Kawai, M., Hagihara, K., Hirano, T.,
Arimitsu, J., Ogata, A., Tanaka, T. and Kawase, I. (2008) Quantiﬁcation of
hardness, elasticity and viscosity of the skin of patients with systemic
sclerosis using a novel sensing device (Vesmeter): a proposal for a new
outcome measurement procedure. Rheumatology 47, 1018–1024.
[115] Shima, Y., Kuwahara, Y., Murota, H., Kitaba, S., Kawai, M., Hirano, T., Arimitsu,
J., Narazaki, M., Hagihara, K., Ogata, A., Katayama, I., Kawase, I., Kishimoto, T.
and Tanaka, T. (2010) The skin of patients with systemic sclerosis softened
during the treatment with anti-IL-6 receptor antibody tocilizumab.
Rheumatology 49, 2408–2412.
[116] Kowal-Bielecka, O., Landewe, R., Avouac, J., Chwiesko, S., Miniati, I., Czirjak, L.,
Clements, P., Denton, C., Farge, D., Fligelstone, K., Foldvari, I., Furst, D.E.,
Muller-Ladner, U., Seibold, J., Silver, R.M., Takehara, K., Toth, B.G., Tyndall, A.,
Valentini, G., van den Hoogen, F., Wigley, F., Zulian, F., Matucci-Cerinic, M.
and EUSTAR Co-Authors (2009) EULAR recommendations for the treatment
of systemic sclerosis: a report from the EULAR scleroderma trials and
research group (EUSTAR). Ann. Rheum. Dis. 68, 620–628.
[117] Dalakas, M.C. (2010) Immunotherapy of myositis: issues, concerns and
future prospects. Nat. Rev. Rheumatol. 6, 129–137.
[118] Lundberg, I., Ulfgren, J.A., Nyberg, P., Andersson, U. and Klareskog, L. (1997)
Cytokine production in muscle tissue of patients with idiopathic
inﬂammatory myopathies. Arthritis Rheum. 40, 865–874.
[119] Lepidi, H., Frances, V., Figarella-Branger, D., Bartoli, C., Machado-Baeta, A. and
Pellissier, J.F. (1998) Local expression of cytokines in idiopathic inﬂammatory
myopathies. Neuropathol. Appl. Neurobiol. 24, 73–79.
[120] Scuderi, F., Mannela, F., Marino, M., Provenzano, C. and Bartoccioni, E. (2006)
IL-6-deﬁcient mice show impaired inﬂammatory response in a model of
myosin-induced experimental myositis. J. Neuroimmunol. 176, 9–15.
[121] Okiyama, N., Sugihara, T., Iwakura, Y., Yokozeki, H., Miyasaka, N. and
Kohsaka, H. (2009) Therapeutic effects of interleukin-6 blockade in a murine
model of polymyositis that does not require interleukin-17A. Arthritis
Rheum. 60, 2505–2512.
[122] Ruitz-Irastorza, G., Khamashta, M.A., Castellino, G. and Hughes, G.R. (2001)
Systemic lupus erythematosus. Lancet 357, 1027–1032.
[123] Linker-Isaraeli, M., Deans, R.J., Wallace, D.J., Prehn, J., Ozeri-Chen, T. and
Klinenberg, J.R. (1991) Elevated levels of endogenous IL-6 in systemic lupus
erythematosus: a putative role in pathogenesis. J. Immunol. 147, 117–123.
[124] Grondal, G., Gunnarsson, I., Ronnelid, J., Rogberg, S., Klareskog, L. and
Lundberg, I. (2000) Cytokine production, serum levels and disease activity in
systemic lupus erythematosus. Clin. Exp. Rheumatol. 18, 565–570.
[125] Peterson, E., Robertson, A.D. and Emlen, W. (1996) Serum and urinary
interleukin-6 in systemic lupus erythematosus. Lupus 5, 571–575.
[126] Iwano, M., Dohi, K., Hirata, E., Kurumatani, N., Horii, Y., Shiiki, H., Fukatsu, A.,
Matsuda, T., Hirano, T., Kishimoto, T. and Dohi, K. (1993) Urinary levels of IL-
6 in patients with active lupus nephritis. Clin. Nephrol. 40, 16–21.
[127] Hirohata, S. and Miyamoto, T. (1990) Elevated levels of interleukin-6 in
cerebrospinal ﬂuid from patients with systemic lupus erythematosus and
central nervous system involvement. Arthritis Rheum. 33, 644–649.[128] Mihara, M., Takagi, N., Takeda, Y. and Ohsugi, Y. (1998) IL-6 receptor blockage
inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin.
Exp. Immunol. 112, 397–402.
[129] Liang, B., Gardner, D.B., Griswold, D.E., Bugelski, P.J. and Song, X.Y. (2006)
Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a
murine model of systemic lupus erythematosus. Immunology 119, 296–305.
[130] Illei, G.G., Shirota, Y., Yarboro, C.H., Daruwalla, J., Tackey, E., Takada, K.,
Fleisher, T., Balow, J.E. and Lipsky, P.E. (2010) Tocilizumab in systemic lupus
erythematosus: data on safety, preliminary efﬁcacy, and impact on
circulating plasma cells from an open-label phase I dosage-escalation
study. Arthritis Rheum. 62, 542–552.
[131] Mendes, D., Correcia, M., Barbedo, M., Vaio, T. and Mota, M. (2009) Behcet’s
disease – a contemporary review. J. Autoimmun. 32, 178–188.
[132] Kulaber, A., Tugal-Tutkun, I., Sibel, P., Akman-Demir, G., Kaneko, F., Gul, A.
and Saruhan-Direskeli, G. (2007) Pro-inﬂammatory cellular immune
response in Behcet’s disease. Rheumatol. Int. 27, 1113–1118.
[133] Hirohata, S., Oka, H. and Mizushima, Y. (1992) Streptococcal-related antigens
stimulate production of IL6 and interferon-gamma by T cells from patients
with Behcet’s disease. Cell. Immunol. 140, 410–419.
[134] Mege, J.L., Dilsen, N., Sanguedolce, V., Gul, A., Bongrand, P., Roux, H., Ocal, L.,
Inanc, M. and Capo, C. (1993) Overproduction of monocyte derived tumor
necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil
superoxide generation in Behcet’s disease. A comparative study with familial
Mediterranean fever and healthy subjects. J. Rheumatol. 20, 1544–1549.
[135] Hirohata, S., Isshiki, K., Oguchi, H., Ohse, T., Haraoka, H., Takeuchi, A. and
Hashimoto, T. (1997) Cerebrospinal ﬂuid interleukin-6 in progressive neuro-
Behcet’s syndrome. Clin. Immunol. Immunopathol. 82, 12–17.
[136] Rachel, R.C. (2010) A look at autoimmunity and inﬂammation in the eye. J.
Clin. Invest. 120, 3073–3083.
[137] Hohki, S., Ohguro, N., Haruta, H., Nakai, K., Terabe, F., Serada, S., Fujimoto, M.,
Nomura, S., Kawahata, H., Kishimoto, T. and Naka, T. (2010) Blockade of
interleukin-6 signaling suppresses experimental autoimmune uveoretinitis
by the inhibition of inﬂammatory Th17 responses. Exp. Eye Res. 91, 162–170.
[138] Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C. and Gage, F.H. (2010)
Mechanisms underlying inﬂammation in neurodegeneration. Cell 140, 918–
934.
[139] Steinman, L. (2008) Nuanced roles of cytokines in three major human brain
disorders. J. Clin. Invest. 118, 3557–3563.
[140] Maimone, D., Gregory, S., Arnason, B.G. and Reder, A.T. (1991) Cytokine levels
in the cerebrospinal ﬂuid and serum of patients with multiple sclerosis. J.
Neuroimmunol. 32, 67–74.
[141] Navikas, V., Matusevicius, D., Soderstrom, M., Fredrikson, S., Kivisakk, P.,
Ljungdahl, A., Hojeberg, B. and Link, H. (1996) Increased interleukin-6 mRNA
expression in blood and cerebrospinal ﬂuid mononuclear cells in multiple
sclerosis. J. Neuroimmunol. 64, 63–69.
[142] Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-
Gould, A., Strober, S., Cannella, B., Allard, J., Klonowski, P., Austin, A., Lad, N.,
Kaminski, N., Galli, S.J., Oksenberg, J.R., Raine, C.S., Heller, R. and Steinman, L.
(2002) Gene-microarray analysis of multiple sclerosis lesions yields new
targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500–508.
[143] Gijbels, K., Van Damme, J., Proost, P., Put, W., Carton, H. and Billiau, A. (1990)
Interleukin 6 production in the central nervous system during experimental
autoimmune encephalomyelitis. Eur. J. Immunol. 20, 233–235.
[144] Serada, S., Fujimoto, M., Mihara, M., Koike, N., Ohsugi, Y., Nomura, S., Yoshida,
H., Nishikawa, T., Terabe, F., Ohkawara, T., Takahashi, T., Ripley, B., Kimura, A.,
Kishimoto, T. and Naka, T. (2008) IL-6 blockade inhibits the induction of
myelin antigen-speciﬁc Th17 cells and Th1 cells in experimental
autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105, 9041–9046.
[145] Jarius, S. and Wildemann, B. (2010) AQP4 antibodies in neuromyelitis optica:
diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 6, 383–392.
[146] Uzawa, A., Mori, M., Ito, M., Uchida, T., Hayakawa, S., Masuda, S. and
Kuwabara, S. (2009) Markedly increased CSF interleukin-6 levels in
neuromyelitis optica, but not in multiple sclerosis. J. Neurol. (Epub ahead
of print).
[147] Icoz, S., Tuzun, E., Kurtuncu, M., Durmus, H., Mutlu, M., Eraksoy, M. and
Akman-Demir, G. (2010) Enhanced IL-6 production in aquaporin-4 antibody
positive neuromyelitis optica patients. Int. J. Neurosci. 120, 71–75.
[148] Collins, P.W. and Percy, C.L. (2009) Advances in the understanding of
acquired hemophilia A: implications for clinical practice. Br. J. Haematol. 148,
182–194.
[149] Nishida, S., Kawasaki, T., Kashiwagi, H., Morishima, A., Hishitani, Y., Kawai,
M., Hirano, T., Ishii, T., Hagihara, K., Shima, Y., Narazaki, M., Ogata, A., Oka, Y.,
Kishimoto, T. and Tanaka, T. (2011) Successful treatment of acquired
hemophilia A, complicated by chronic GVHD, with tocilizumab. Mod.
Rheumatol. (Epub ahead of print).
[150] Gergis, U., Arnason, J., Yantiss, R., Shore, T., Wissa, U., Feldman, E. and
Woodworth, T. (2010) Effectiveness and safety of tocilizumab, an anti-
interleukin-6 receptor monoclonal antibody, in a patient with refractory GI
graft-versus-host disease. J. Clin. Onocol. 28, 602–604.
[151] McDermott, M.F., Aksentijevick, I., Galon, J., McDermott, E.M., Ogunkolande,
B.W., Centola, M., Mansﬁeld, E., Gadina, M., Karenko, L., Pettersson, T.,
McCarthy, J., Frucht, D.M., Aringer, M., Torosyan, Y., Teppo, A.M., Wilson, M.,
Karaarslan, H.M., Wan, Y., Todd, I., Wood, G., Schlimgen, R., Kumarajeewa,
T.R., Cooper, S.M., Vella, J.P., Amos, C.I., Mulley, J., Quane, K.A., Molloy, M.G.,
Ranki, A., Powell, R.J., Hitman, G.A., O’Shea, J.J. and Kastner, D.L. (1999)
Germline mutations in the extracellular domains of the 55 kDa TNF receptor,
T. Tanaka et al. / FEBS Letters 585 (2011) 3699–3709 3709TNFR1, deﬁne a family of dominantly inherited autoinﬂammatory
syndromes. Cell 97, 133–144.
[152] Vaitla, P.M., Radford, P.M., Tighe, P.J., Powell, R.J., McDermott, E.M., Todd, I.
and Drewe, E. (2011) Role of interleukin-6 (IL-6) in a patient with TRAPS
revealed by treatment with tocilizumab (anti-IL-6 receptor monoclonal
antibody). Arthritis Rheum. (Epub ahead of print).
[153] Campbell, L., Chen, C., Bhagat, S.S., Parker, R.A. and Ostor, A.J. (2010) Risk of
adverse events including serious infections in rheumatoid arthritis patients
treated with tocilizumab: a systemic literature review and meta-analysis of
randomized controlled trials. Rheumatology (Epub ahead of print).[154] Wallenius, V., Wallenius, K., Ahren, B., Rudling, M., Carlsten, H., Dickson, S.L.,
Ohlsson, C. and Jansson, J.-O. (2002) Interleukin-6-deﬁcient mice develop
mature-onset obesity. Nat. Med. 8, 75–79.
[155] Kishimoto, T. (2010) IL-6: from its discovery to clinical applications. Int.
Immunol. 22, 347–352.
[156] Fujimoto, M., Serada, S., Mihara, M., Uchiyama, Y., Yoshida, H., Koike, N.,
Ohsugi, Y., Nishikawa, T., Ripley, B., Kimura, A., Kishimoto, T. and Naka, T.
(2008) Interleukin-6 blockade suppresses autoimmune arthritis in mice by
the inhibition of inﬂammatory Th17 responses. Arthritis Rheum. 58, 3710–
3719.
